Product Information
AZILECT 0.5 MG TABLET is a brand product labeled by Teva Neuroscience, Inc., priced at $44.0463 per EA under NDC 68546014256. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 16, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Teva Neuroscience, Inc.NDC
68546014256
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
RASAGILINE MESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA021641FDA Approved
5/16/2006
TE Code
AB
On Market Since
7/10/2006
Pharmacological Classes
Price Statistics
The NADAC for AZILECT 0.5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 215.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $44.0463 per EA |
|---|---|
| All-time high | $44.0463 (Sep 30, 2026) |
| All-time low | $13.9649 (Nov 28, 2013) |
| 52-week high | $44.0463 |
| 52-week low | $40.2617 |
| Median price | $26.7941 |
| Average price | $27.6503 |
| Largest weekly change | +9.9% (Jan 7, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Neuroscience, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rasagiline mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Monoamine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AZILECT 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AZILECT 0.5 MG TABLET, manufactured by Teva Neuroscience, Inc., is $44.0463 per EA (NDC 68546014256), effective Sep 30, 2026.
How has the price of AZILECT 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for AZILECT 0.5 MG TABLET has risen 215.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AZILECT 0.5 MG TABLET?
Since Nov 28, 2013, the NADAC for AZILECT 0.5 MG TABLET has ranged from a low of $13.9649 (Nov 28, 2013) to a high of $44.0463 (Sep 30, 2026), with a median of $26.7941 per EA.
Are there cheaper alternatives to AZILECT 0.5 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RASAGILINE MESYLATE 0.5 MG TAB, is $0.5209 per EA — about 99% below AZILECT 0.5 MG TABLET.
Who manufactures AZILECT 0.5 MG TABLET?
AZILECT 0.5 MG TABLET (NDC 68546014256) is labeled by Teva Neuroscience, Inc., and CMS classifies it as a brand product.